Table 1.

Demographics and baseline characteristics of the study population

CharacteristicsNon-Coronavirus Disease 2019, n=810Coronavirus Disease 2019, n=8
Age, yr57 (47–67)55 (48–66)
Sex, women, n (%)407 (50)6 (75)
Current smoker, n (%)163 (20)0
Body mass index, kg/m222.3 (20.3–24.2)23.0 (19.5–24.7)
Primary cause of kidney failure, n (%)
 Diabetic kidney disease128 (16)2 (25)
 GN99 (12)3 (38)
 Hypertensive kidney disease279 (34)2 (25)
 Polycystic kidney disease5 (0.6)0
 Lupus nephritis9 (1)0
 Obstructive uropathy4 (0.5)1 (13)
Coexisting diseases, n (%)
 Diabetes78 (10)2 (25)
 Hypertension235 (29)7 (88)
 Cardiovascular disease276 (34)7 (88)
 Respiratory disease19 (2)0
 Cancer5 (0.6)0
Previous dialysis modality, n (%)
 CAPD723 (89)8 (100)
 APD9 (1)0
 DAPD29 (4)0
 Peritoneal dialysis + hemodialysis54 (7)0
Total Kt/Vurea1.8 (1.5–2.3)1.6 (1.5–2.1)
Ultrafiltration, ml/d626±365588±247
Residual urine production, ml/d424±516250±207
ACEI/ARB use, n (%)N/A7 (88)
Symptoms, n (%)N/A
 Fever5 (63)
 Cough2 (25)
 Sputum production0 (0)
 Dyspnea2 (25)
 Fatigue4 (50)
Radiologic findings, n (%)N/A
 Ground glass/patchy opacity7 (88)
 Fibrosis3 (38)
 Consolidation0 (0)
 Pulmonary nodule0 (0)
 Bilateral lesions7 (88)
Laboratory findings, n (%)
 Leukocyte, /μl4880 (3560–6680)7130 (5120–1048)
 Platelet count, 103/μl189 (151–233)188 (155–228)
 Hemoglobin, g/dl10.1±2.28.8±2.4
 Neutrophil count, /μl4500 (3410–6080)6110 (3970–1045)
 Lymphocyte count, /μl1300 (1000–1670)730 (600–1030)
 Eosnophil count, /μl200 (120–330)60 (40–120)
 Serum albumin, g/dl3.6 (3.3–3.9)2.9 (2.5–3.6)
 ALT, U/L15 (10–20)18 (8–48)
 AST, U/L15 (11–21)24 (16–29)
 Serum creatinine, mg/dl9.98 (7.82–12.40)10.85 (8.68–12.73)
 Serum BUN, mg/dl50.4 (39.2–61.6)56.0 (36.4–70.0)
 Serum uric acid, mg/dl6.28 (5.21–7.32)7.19 (6.38–9.58)
 Fasting blood glucose, mg/dl82.8 (21.6–104.4)131.4 (111.6–144)
 C-reactive protein, ≥1 mg/dl73 (9)5 (7)
Positive NATN/A7 (88)
Positive antibody, n (%)N/A5
 IgM0
 IgG4 (80)
Days from onset to antibody detection25 (20–34)
Disease severity, severe, n (%)N/A2 (25)
Treatment, n (%)N/A
 Antiviral agents6 (75)
 Antibacterial agents5 (63)
 Chloroquine phosphate1 (13)
 Glucocorticoids0 (0)
 Ig0 (0)
 Mechanical ventilation0 (0)
Complications, n (%)N/A
 Acute hepatic injury4 (50)
 Acute cardiac injury2 (25)
 Heart failure4 (50)
 Cerebrovascular event1 (13)
 Peritonitis1 (13)
 Hypokalemia4 (50)
 Hypocalcemia2 (25)
 ARDS0 (0)
Outcome, n (%)N/A
 Recovered6 (75)
 Deceased2 (25)
  • Continuous variables were described as median and interquartile range or mean and SD, and differences were assessed using analysis of t test or Mann–Whitney U test. Categorical variables were expressed as number (percentage), and differences between groups were assessed using the Fisher exact test. ARDS was defined according to the Berlin definition. Acute cardiac injury was diagnosed if the serum levels of cardiac biomarkers (e.g., troponin I) were above the 99th percentile upper reference limit or new abnormalities were shown in electrocardiography and echocardiography. Acute hepatic injury was defined as an elevation in AST or ALT of >15 times the upper limit of normal. CAPD, continuous ambulatory peritoneal dialysis; APD, automated peritoneal dialysis; DAPD, daytime ambulatory peritoneal dialysis; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; N/A, not available; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NAT, nucleic acid testing; ARDS, acute respiratory distress syndrome.